SMMT is currently developing the following drugs: Ivonescimab Injection, Pembrolizumab Injection, Ivonescimab Injection, Pembrolizumab Injection, Oxaliplatin, Irinotecan, Capecitabine, Leucovorin, 5-Fluorouracil, Ak112, Ak117. These drug candidates are in various stages of clinical development as the company works toward FDA approval.